Brief Description
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.
Sunesis was co-founded by UC Berkeley Professor of Chemistry Jonathan Ellman.
Formerly known as Mosaic Pharmaceuticals.
Timeline
- 1998. Company founded
- 2005. Initial public offering on NASDAQ with the ticker symbol SNSS
- 2021. Sunesis acquired by Viracta Therapeutics through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker symbol VIRX
Inventors
Ingrid Choong, Jonathan Ellman